2M6 Stock Chart & Stats
€74.74
€1.42(1.94%)
At close: 4:00 PM EDT
€74.74
€1.42(1.94%)
Day’s Range― - ―
52-Week Range€62.86 - €91.50
Previous CloseN/A
Volume1.49K
Average Volume (3M)1.71K
Market Cap
€103.07B
Enterprise Value€127.87K
Total Cash (Recent Filing)€9.22B
Total Debt (Recent Filing)€27.96B
Price to Earnings (P/E)24.6
Beta0.30
Next Earnings
Sep 01, 2026EPS Estimate
1.19Next Dividend Ex-DateN/A
Dividend Yield3.03%
Share Statistics
EPS (TTM)3.75
Shares Outstanding1,280,045,200
10 Day Avg. Volume1,970
30 Day Avg. Volume1,711
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)2.16
Price to Sales (P/S)2.94
P/FCF Ratio19.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€81.80Price Target Upside9.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)5.14
Revenue Forecast (FY)€33.60B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent revenue expansion indicates broad demand across Medtronic’s chronic-care portfolio and improving commercial execution. The FY27 organic growth outlook of 6.75%–7.25% supports continued momentum over the next several quarters.
Strong Cash GenerationRobust operating and free cash flow provide durable funding for research, acquisitions, dividends, and debt service. Healthy free-cash-flow conversion also supports earnings quality and gives Medtronic flexibility to invest through industry cycles.
Innovation And Share GainsRapid growth in cardiac ablation and progress in robotics and renal denervation show that newer platforms are gaining adoption. These differentiated therapies can diversify the portfolio, expand the addressable market, and support future recurring procedure revenue.
Bears Say
Meaningful Debt LoadAlthough leverage is moderate relative to equity and the balance sheet is stable, the absolute debt burden remains significant. A sustained profitability downturn or higher financing costs could reduce flexibility for acquisitions, investment, and shareholder distributions.
Tariff And Trade ExposureTariffs represent an ongoing cost and supply-chain risk rather than a one-quarter issue. Unless mitigated through pricing, sourcing, or manufacturing changes, they could constrain gross-margin improvement and weaken the returns from Medtronic’s international operations.
Structural Heart WeaknessWeakness in TAVR and coronary products challenges an important cardiovascular franchise and may persist while physicians reassess patient selection after new clinical data. Stabilization efforts could take time, limiting growth and increasing pressure on portfolio mix.
Medtronic News
2M6 FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was €62.86 and its highest was €91.50 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is €103.07B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Sep 01, 2026 which is in 11 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Jun 03, 2026. The company reported €1.326 earnings per share for the quarter, beating the consensus estimate of €1.317 by €0.009.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of €0.615 which represents an annual dividend yield of 3.03%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.19.
How many shares outstanding does Medtronic have?
Medtronic has 1,280,045,200 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of €1.326 in its last earnings report, beating expectations of €1.317. Following the earnings report the stock price went up 4.336%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in DE:2M6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€81.80 (9.45% Upside)
€81.80 (9.45% Upside)
Blogger Sentiment
Bullish
DE:2M6 Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €288.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.93%
12-Months-Change
Fundamentals
Return on Equity
3.03%
Trailing 12-Months
Asset Growth
1.47%
Trailing 12-Months
Company Description
Medtronic
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
2M6 Company Deck
2M6 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong quarterly and annual revenue growth, EPS outperformance, robust free cash flow, multiple high-growth product area accelerations (CAS, Symplicity, Hugo, Altaviva), and deliberate M&A/venture activity to drive future growth. Notable headwinds include tariffs and trade uncertainty, some product‑mix and Diabetes-related margin pressure, pockets of weakness in Structural Heart (TAVR) and select therapy areas, and near-term investment-driven SG&A/R&D increases. Management provided confident FY '27 guidance while conservatively modeling separation and tariff risks.View all DE:2M6 earnings summaries2M6 Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
2M6 Stock 12 Month Forecast
Average Price Target
€81.80
▲(9.45% Upside)